Reprogrammed SimCells for antimicrobial therapy

Yun Jiang Dong, Xingrui Ji, Tao Dong, Yun Wang, Erik Bakkeren, Kevin R. Foster, Weilin HuangProceedings of the National Academy of Sciences 2026 · DOI

TL;DR

Researchers have engineered "SimCells" and "mini-SimCells" – essentially cell-like particles without their own chromosomes – to combat antibiotic-resistant bacteria. These tiny biological machines selectively target and destroy harmful bacteria using two distinct mechanisms: a direct "nano-needle" attack and the localized production of a toxic molecule, offering a promising new strategy against the growing threat of AMR.

What Problem Does This Paper Address?

Antimicrobial resistance (AMR) is a major global health crisis, with drug-resistant infections predicted to cause millions of deaths and trillions in economic losses annually. While new antibiotics are desperately needed, their discovery has slowed, and existing ones are becoming less effective as bacteria evolve resistance. This necessitates the development of alternative therapeutic strategies. Traditional engineered bacteria for therapy face challenges with biocontainment and uncontrolled replication. This paper addresses the need for a highly specific, efficient, and safe antimicrobial platform that can overcome AMR, by leveraging engineered, non-replicating cell-like particles.

Methods

The core innovation lies in the development and application of "SimCells" and "mini-SimCells." These are derived from E. coli but have their native chromosomes removed, rendering them non-replicating and thus safer.

  • SimCells and Mini-SimCells Production: SimCells are created by inducing chromosomal DNA degradation. Mini-SimCells are produced via asymmetric cell division. Both are engineered to carry specific genetic modules.
  • Surface Display of Nanobodies: Nanobodies, small antibody fragments, are engineered to be displayed on the outer membrane of SimCells and mini-SimCells. This allows them to specifically bind to antigens (like OmpA) on target bacteria.
  • Type VI Secretion System (T6SS) Integration: A T6SS system is incorporated into the SimCells/mini-SimCells. This system acts like a "nano-needle" to directly inject toxic effectors into the cytoplasm of bound target bacteria.
  • Enzymatic Conversion for H₂O₂ Production: The salicylate hydroxylase (NahG) enzyme is expressed. This enzyme converts ingested aspirin into catechol, which then auto-oxidizes to produce hydrogen peroxide (H₂O₂), a potent antimicrobial agent.
  • Dual-Mechanism Strategy: The platform combines nanobody-mediated targeting with either T6SS-mediated killing or H₂O₂ production, or both, for enhanced efficacy.
  • Characterization Techniques: Standard microbiological techniques (growth curves, CFU counting), microscopy (fluorescence, SEM), flow cytometry, and ZetaView analysis were used to characterize cell properties, binding, and killing efficiency.

Datasets

Not discussed in the paper. The study focuses on experimental validation using engineered bacterial strains and their interactions with target pathogens.

Key Insights and Ideas

  • Non-replicating "Smart" Bioparticles: The development of chromosome-free SimCells and mini-SimCells offers a significant biosafety advantage over traditional engineered bacteria, eliminating concerns about uncontrolled proliferation.
  • Modular "Plug-and-Play" Design: The platform's modularity, allowing for the easy swapping of nanobodies for different targets and the integration of various killing mechanisms, makes it highly adaptable for combating diverse AMR pathogens.
  • Synergistic Dual-Mechanism Killing: Combining T6SS-mediated direct attack with H₂O₂ generation from aspirin creates a powerful synergistic effect, leading to significantly higher killing efficiencies and sustained activity.
  • Targeted Delivery is Key: The nanobody-antigen recognition is crucial for ensuring that the antimicrobial mechanisms are delivered precisely to the target bacteria, minimizing off-target effects on beneficial microbes.
  • Overcoming Resistance: The platform demonstrates effectiveness against a clinically relevant multidrug-resistant strain (E. coli ST131), suggesting its potential to circumvent existing resistance mechanisms.

Key Results

  • Selective Binding: Engineered SimCells and mini-SimCells with nanobodies showed rapid and specific aggregation with target bacteria expressing the corresponding antigen.
  • Efficient Killing:
    • A single dose of reprogrammed mini-SimCells eliminated 94% of target E. coli within 24 hours and 99% within 48 hours.
  • In mixed microbial communities, multidose treatment achieved a 10³-fold selective reduction of targeted bacteria.
  • Against the multidrug-resistant E. coli ST131, mini-SimCells achieved over 97% elimination within 24-48 hours.
  • Minimal Disruption: The system showed minimal disruption to nontarget bacteria in mixed communities.
  • No Detectable Resistance: Repeated exposure to the dual-mechanism mini-SimCells did not readily induce resistance in the target bacteria, unlike conventional antibiotics.
  • Low Cytotoxicity: Reprogrammed mini-SimCells exhibited negligible cytotoxicity towards mammalian cells (HEK293) even at high doses, indicating a favorable safety profile.

Limitations and Future Work

  • In Vivo Efficacy: While promising in vitro results are shown, further studies are needed to demonstrate efficacy and safety in animal models and eventually human clinical trials.
  • Complex Microbiomes: The authors suggest that future work should involve validation in more complex polymicrobial communities that better represent native microbiomes.
  • Nanobody Reservoir Expansion: Expanding the library of nanobodies targeting a wider range of AMR pathogens is crucial for broad applicability.
  • Antigen Variation: The potential for AMR pathogens to mutate surface antigens, leading to escape from nanobody recognition, is acknowledged. The authors propose using multi-nanobody cocktails to mitigate this.
  • Long-Term Resistance Evolution: While in vitro studies showed no rapid resistance development, long-term studies are needed to fully assess this aspect.
  • Scalability and Manufacturing: While the production of SimCells and mini-SimCells is described as scalable, further optimization for large-scale industrial manufacturing might be necessary.

Summary updated

Abstract

Antimicrobial resistance (AMR) is a critical global health challenge. In this study, we developed a platform based on chromosome-free and nonreplicating simple cells (SimCells, size 1 to 2 µm) and mini-SimCells (size 100 to 400 nm) for targeted pathogen elimination. Engineered with surface-displayed nanobodies, SimCells and mini-SimCells selectively bind bacteria expressing specific antigens (e.g., OmpA in <i>Escherichia coli</i>). The selective interactions facilitate close SimCell-pathogen proximity, enabling two antimicrobial mechanisms: direct injection of toxic effectors into bacterial cytoplasm via a heterologous expression of type VI secretion system (T6SS), and enzymatic conversion of aspirin into catechol by engineered salicylate hydroxylase, leading to sustained local production of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Our results demonstrate that both reprogrammed SimCells and mini-SimCells can eliminate target <i>E. coli</i> with high specificity and efficiency. Multidose reprogrammed mini-SimCell treatment led to a 10<sup>3</sup>-fold selective reduction of targeted bacteria in mixed microbial communities, with minimal disruption to nontarget bacteria. We demonstrate that reprogrammed mini-SimCells, engineered with nanobody targeting outer membrane protein OmpA of the clinically relevant multidrug-resistant pathogen <i>E. coli</i> ST131, achieved elimination efficiencies over 97% at 24 and 48 h. This modularized "plug-and-play" antimicrobial platform provides a highly specific, efficient, and adaptable solution for combating diverse AMR pathogens.
BibTeX
@inproceedings{dong2026reprogrammed,
  author = {Yun Jiang Dong and Xingrui Ji and Tao Dong and Yun Wang and Erik Bakkeren and Kevin R. Foster and Weilin Huang},
  title = {{Reprogrammed SimCells for antimicrobial therapy}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2517118123},
}
Figure